Trial Profile
A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblasts for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2019
Price :
$35
*
At a glance
- Drugs ICX-RHY (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Therapeutic Use
- Sponsors Intercytex
- 14 Jul 2019 Status changed from recruiting to completed.
- 03 Nov 2014 New trial record